Trial Profile
An Open, Single Arm,Multicenter Clinical Trial of Anlotinib Combined With Transcatheter Arterial Chemoembolization for Adjuvant Therapy in Patients With High Risk of Recurrence After Resection of Advanced Hepatocellular Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Mar 2024
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms ALTER-H-004
- 20 Jan 2024 Results (data cut off March 2023) assessing efficacy and safety of anlotinib as maintenance adjuvant treatment following inductional TACE in patients with hepatocellular carcinoma were presented at the 2024 Gastrointestinal Cancers Symposium
- 06 Jun 2023 Updated results (at data cut off: January 15, 2023; n=29) presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 12 Jan 2023 Planned End Date changed from 1 Jun 2022 to 1 Sep 2023.